Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab plus chemotherapy as neoadjuvant therapy in triple-negative breast cancer
ChiCTR2600122486Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Apr 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab in triple-negative breast cancer (TNBC), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Pathological Complete Response Rate (pCR, ypT0/is ypN0). Planned start Apr 2026; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR2600122486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122486.